01:03 , Jan 4, 2019 |  BC Week In Review  |  Company News

Tetra grants Shionogi Asian rights to Alzheimer's/fragile X candidate

Shionogi & Co. Ltd. (Tokyo:4507) received from Tetra Discovery Partners LLC (Grand Rapids, Mich.) exclusive rights in Japan, Korea and Taiwan to develop BPN14770 to treat brain disorders associated with dementia, including Alzheimer's disease and...
19:00 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Tetra reports preliminary Phase I data for AD candidate BPN14770

Tetra Discovery Partners LLC (Grand Rapids, Mich.) reported preliminary data from a Phase I trial in 45 healthy elderly volunteers showing that twice-daily 10 and 20 mg oral doses of Alzheimer's disease candidate BPN14770 for...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

BPN14770: Phase I started

Tetra began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of oral BPN14770 in about 48 healthy volunteers. Tetra Discovery Partners LLC , Grand Rapids, Mich.   Product: BPN14770   Business:...
01:33 , Dec 31, 2015 |  BC Extra  |  Clinical News

Tetra candidate backed by NIH's Blueprint enters clinic

Tetra Discovery Partners LLC (Grand Rapids, Mich.) began Phase I testing of BPN14770 , the first candidate funded by NIH's Blueprint Neurotherapeutics Network (BPN) to reach the clinic. The negative allosteric modulator of phosphodiesterase-4D (...